Thank you very much. And hello and welcome to Cinclus Pharma first quarter 2026 earnings call. As you already know, I'm Christer Ahlberg, CEO of Cinclus Pharma. And with me here today, I also have our CFO, Magnus Christensen, and our R&D director, Margit Mahlapuu.
We will walk you through the key developments from the first quarter, and thereafter, we will be happy to answer any questions you may have. So let's go in then directly to the presentation. As you know, our lead asset, Linaprazan glurate, is the next-generation PCAB built around one defining property: sustained, around-the-clock acid control that differentiates the substance from both PPIs and the rest of the PCABs, especially in severe erosive GERD, which is our target population. The patient population we are addressing is large and underserved. Approximately 90 million patients worldwide, including 10 million patients from the U.S. and Europe. And these patients do have severe erosive GERD, and a substantial share of them are not adequately healed on today's standard of care, including PCABs.
The gap is what makes the specialty-driven commercial opportunity rather than a primary care one. Better healing and better symptom control translate directly into clinical and commercial differentiation.
So, that's important for us; our Phase III program, based on the strong Phase II results we generated previously, began last year in October; and our first study, HEEALING 1, has had very good progress; and we will learn more about that later in this presentation. And we are actually approaching full enrollment in this HEEALING 1 study. And we have now good visibility on the timelines with expected topline results in Q4 already in this year. And this will, of course, be a major value catalyst. And as I said, Margit will tell you more about this later during this presentation.
Our program is well de-risked at this stage. We have a robust clinical data package and alignment from both FDA and EMA.
Our regulatory strategy.
And we have a very well-defined CMC plan. The plan is also aligned with the authorities, and PCABs are gaining significant global momentum.
Now available in more than 30 countries and increasingly incorporated into treatment guidelines, which is important. Further validating the mechanism of action and expanding the long-term commercial opportunity for Linaprazan glurate, our substance.
And we have, as you already know, a license agreement with Zentiva in Europe worth up to €220 million. This cooperation works well. Very well.
We also have a license agreement with Sinorda for selected markets in Asia. And in fact, we already have communicated.
Linaprazan glurate is now launched in China by its Sinorda partner during Q1. Our Sinorda partner is in China, and now we have an ongoing local reimbursement application. But at the end of last year, we actually received the national reimbursement in China. So that's very positive.
And this chart is a slide that makes a short point. This makes a simple but important point. We see how. How well a drug controls gastric acid over a 24-hour day predicts how well it will heal erosive GERD. The relationship is totally linear, as you see. It doesn't matter if we're talking about PPIs or other PCABs, the biomarkers are there and the correlation is there for all of these drugs. This is a central scientific argument for our program. Our acid control is the biomarker that drives healing in this disease. And the more of the day you can keep the gastric pH above four, the greater chances you have to heal the patients. And that is precisely the variable and the differentiation factor that differentiates Linaprazan glurate, how it's positioned, and how we have built and developed the product. These slides illustrate the number of hours that pH in the stomach is below pH four. With different treatment alternatives. You can see the evolution of this on the market here for decades, where you started with the H2 blockers on the top row, showing the acid control in percentage over the 24 hours, meaning pH above four. And in the diagram there, you can see the number of hours where you are below pH four.
Below pH four gives you a risk.
There is a risk.
Each hour you are below. There is a risk that you could get erosions and symptoms based on the acidic content coming up in the esophagus.
H2 blockers 16 hours below pH four. There was a major development when PPIs came to the market. You can see the giant leap there. That was the reason why they became so popular and became the best-selling drug in the world.
We can now see the pH has another giant leap going into the first generation of PCABs from PPI. And that's the reason why PCABs have become so popular. They improved acid control. But you can see the same giant leap from the first-generation PCABs to our drug, Linaprazan glurate, in the number of hours of improvement.
And this is why we believe it can be done again. This is the reason to believe in the effective differentiation and positioning of the product. So we actually now have a product that offers a solution for the disease and helps patients with severe erosive GERD. But if you also look into this clinically, not only from an acid control perspective, we can actually plot the data into this diagram or biomarker diagram that I showed you earlier.
And now we have also all the data, all the healing data from both Vonoprazan and now also from Tegoprazan, the second PCAB in the US.
What you can see here is that their drug has also been compared to the PPI Lansoprazole. What you can see here is that it's perfectly spot on to the linear correlation here with the Lansoprazole on 63% pH control. And the data shows healing rate of the C and D in eight weeks of 60 to 70%. Tegoprazan just last week presented their healing data with 75% acid control; they delivered approximately 80% healing rate on C and D patients. And previously we already know about Vonoprazan acid control between 65 to 85% and with a healing rate of approximately 90%.
As we already have communicated, and what we have seen in our data is that we have acid control of 96%. So it will be very interesting to follow. Now, the topline results from our first pivotal Phase III trial are coming up later this year. So it looks indeed very promising here. So, to summarize the differentiation factors, as it becomes more and more obvious how to promote this product as best in class, you can see the acid control of Linaprazan glurate at 96%, in comparison to PPIs at 40-70%, and first-generation PCABs like Vonoprazan at 63-85% and Tegoprazan now at 75%. We have a very fast onset. We reach full effect after the first dose in an hour.
And that is of course important for many different perspectives. And the good acid control gives us a very good effect. We have in our Phase II data in the best cohort there, delivered a 55 percentage points better healing effect in the severe patient in four weeks compared to Lansoprazole.
So, a 55 percentage point difference, or delta. And that should be in comparison to what we now see with Vonoprazan and Tegoprazan, and the products that now have ambitions relevant for us, where they have a delta effect of approximately 15 to 20% over 2 to 8 weeks.
So this is a huge difference. As you can see, we have more than double the delta compared to what they have.
Our ambition is to heal patients in half the time, four weeks instead of eight weeks, which is the standard of this treatment thanks to this fast and great acid control.
And of course, we are looking into the symptom relief and delivering superiority there as well, especially focusing on the nighttime symptom, which is something that every second patient is complaining about, especially pain during nighttime. So this is how we're going to differentiate the product.
And also, I just wanted to mention things. The financing structure. We finalized during the quarter. So in March, we entered into a long-term structured credit agreement with Claret Capital Partners, Europe's largest independent growth debt fund manager.
The total amount is up to €28 million. The financing is divided into a four-tranche structure, a secured loan facility with warrants and convertibles, and is aligned with key clinical and operational milestones in our program. We draw down an initial €8 million tranche, and that's tranche A at signing already in March.
This new capital allows us to look beyond the HEEALING 1 readout and to begin the preparatory work for the next pivotal HEEALING 2 trial in parallel, rather than do it sequentially. So, the intention is that we can move efficiently toward our final Phase III milestone while minimizing the dilution of existing shareholders. It also contributes to financing the remaining development and pre-launch activity of Linaprazan glurate.
This is an important deal that we have done, and it will be very supportive for the future. Here are the key events in February.
We received positive feedback from the EMA on the CMC, the Chemistry, Manufacturing and Controls strategy for Linaprazan glurate. EMA confirmed that our planned CMC approach is well aligned with the requirements from the agency. For the upcoming marketing authorization application, we got similar positive FDA feedback last autumn, and we now have consistent alignment from both EMA in Europe and FDA in the US on our CMC strategy.
This is really important also.
FDA provided a positive assessment of our non-clinical development plan following a scientific advice meeting. They concluded that based on the current data package, no additional toxicology studies are required ahead of the future NDA submission.
This reduces the development risk and contributes to a more time and resource efficient path to the filing. In February. And of course, severe erosive GERD is included in that. And that's of course, GERD is included in that.
This confirms that our current Phase III program is considered a sufficient basis for regulatory submission in the US. In addition to the European ones. And as I also just mentioned, we signed a €28 million financing agreement with Claret Capital Partners, of which €8 million is already drawn in March. Also, I just mentioned, our licensee Sinorda and its local partner Huadong have during the quarter launched Linaprazan glurate on the Chinese market, which of course is an important milestone for us.
So to conclude, we have continued to take important steps and have strengthened our position in this past quarter. So with that, I will pass it to Margit for Phase III HEEALING 1 study update.
Margit. So please go ahead.